LBA69 Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer.
Saved in:
| Title: | LBA69 Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer. |
|---|---|
| Authors: | Langley, R.E.1 (AUTHOR), Nankivell, M.1 (AUTHOR), Gilbert, D.1 (AUTHOR), Bourmpaki, E.1 (AUTHOR), Mangar, S.2 (AUTHOR), Rush, H.L.1 (AUTHOR), Rosen, S.D.3 (AUTHOR), Alhasso, A.4 (AUTHOR), Kockelbergh, R.5 (AUTHOR), Marshall, J.1 (AUTHOR), Griffiths, A.1 (AUTHOR), Chan, K.H.Y.1 (AUTHOR), Mohamed, W.M.6 (AUTHOR), Dallas, N.L.7 (AUTHOR), Brown, S.J.8 (AUTHOR), Clarke, N.9 (AUTHOR), James, N.D.10 (AUTHOR), Parmar, M.K.1 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1258-S1258. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
